ClinicaliQ Trial Snapshot
- A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer — Active Not Recruiting • Phase III • Oncology • NCT03748641.
- Adding niraparib to standard prostate cancer treatment (abiraterone and prednisone) delays cancer progression compared to standard treatment alone.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo. Conditions: Castration-Resistant Prostatic Cancer Interventions: Niraparib, Abiraterone Acetate, Prednisone, Placebo, New Formulation of Niraparib and Abiraterone Acetate (AA) Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 765 participants